Pulido Jose S

Mano Fukutaro, Yonekawa Yoshihiro, Kakihara Shinji, Fortun Jorge, Borrelli Enrico, Bandello Francesco et al.

Most amyloidosis patients show choroidal amyloid angiopathy on late ICGA, with maximal staining up to 12.5 minutes. This angiopathy often improves with systemic treatment, potentially indicating disease status and guiding management.

Mano Fukutaro, Gandhi Jarel K, da Silva Raphael Pereira, Silva Aline Do Amaral, Iezzi Lucas, Iezzi Raymond et al.

Researchers improved pig subretinal implantation surgery by precauterizing the choroid and using an enhanced inserter, reducing bleeding and hypotony. This advances implant-based therapies by improving surgical outcomes.

Cohen Devon A, Bhatti M Tariq, Pulido Jose S, Lennon Vanda A, Dubey Divyanshu, Flanagan Eoin P et al.

CRMP5 IgG-positive patients often present with optic disc edema, retinitis, or uveitis, commonly preceding cancer. Testing for CRMP5 IgG is crucial for timely treatment and cancer screening to preserve vision.

Dalvin Lauren A, Yu Michael D, Ancona-Lezama David Arturo, Pulido Jose S, Olsen Timothy W, Shields Carol L

This study found peripheral retinal non-perfusion in 34% of retinal haemangioblastoma cases, especially with larger, more peripheral tumors in younger VHL patients, increasing neovascularization and vision loss risk.

Mansukhani Sasha A, Barkmeier Andrew J, Bakri Sophie J, Iezzi Raymond, Pulido Jose S, Khanna Cheryl L et al.

Mansukhani Sasha A, Barkmeier Andrew J, Bakri Sophie J, Iezzi Raymond, Pulido Jose S, Khanna Cheryl L et al.

This study found vitrectomy significantly increases the 10-year risk of primary open-angle glaucoma (POAG). Clinically, this highlights the need for long-term POAG screening after vitrectomy.

Itty Sujit, Pulido Jose S

Kapur Rashmi, Pulido Jose S, Abraham Jerrold L, Sharma Mithlesh, Buerk Bruce, Edward Deepak P

Surgical removal of massive optic nerve head drusen revealed calcium phosphate composition, suggesting its role in neuronal damage. Excision is technically possible but carries high risk and requires better tools/patient selection.

Bakri Sophie J, Snyder Melissa R, Reid Joel M, Pulido Jose S, Ezzat Mohamed K, Singh Ravinder J

This rabbit study found intravitreal ranibizumab has a 2.88-day vitreous half-life, shorter than bevacizumab, with no systemic or fellow-eye detection, suggesting a favorable safety profile.

Amselem Luis, Montero Javier, Diaz-Llopis Manuel, Pulido Jose S, Bakri Sophie J, Palomares Paula et al.

Intravitreal bevacizumab in two OIS patients reduced iris neovascularization and macular edema, suggesting it may be a useful treatment for these complications.

Bakri Sophie J, Snyder Melissa R, Reid Joel M, Pulido Jose S, Singh Ravinder J

This rabbit study found intravitreal bevacizumab (1.25mg) has a vitreous half-life of 4.32 days, maintaining therapeutic levels for 30 days, with minimal systemic exposure, guiding dosing for retinal conditions.